Video

ESC 2017: FOURIER - Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab

Published: 25 Sep 2017

  • Views:

    Views Icon 66
  • Likes:

    Heart Icon 0

This interview with Robert Giugliano from Brigham and Women's Hospital, Boston, US discusses the Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab (FOURIER).

Filmed by Radcliffe Cardiology on-site at ESC 2017.